Press Releases
 
Hemophilia Management Market Research Available in New Report

Hemophilia Management Market

, 16 January 2019 -- Hemophilia Management Market is mainly driven by growing prevalence of the disease; market for Hemophilia Management is also boosted by increasing use of recombinant products and prophylactic regimens

Hemophilia is an inherited bleeding disorder which prevents blood clotting. People born with hemophilia have little or no clotting factor. Clotting factor is a protein needed for normal blood clotting. There are several types of clotting factors. These proteins work with platelets to help the blood clot. About 7 out of 10 people who have hemophilia A have the severe form of the disorder. People who don't have hemophilia have a factor VIII activity of 100 percent. People who have severe hemophilia A have a factor VIII activity of less than 1 percent. Hemophilia usually occurs in males. About 1 in 5,000 males are born with hemophilia each year. There are two main types of hemophilia such as Hemophilia A which is due to factor VIII deficiency and Hemophilia B which is due to factor IX deficiency. They are clinically almost identical and are associated with spontaneous bleeding into joints, muscles and internal or external bleeding after injury or surgery.

Read Report Overview: https://www.transparencymarketresearch.com/hemophilia-management-market.html

There are three levels of Hemophilia severity like severe, moderate and mild. Severe means 0%-1% factor level: about 80% of hemophilia sufferers are considered severe. Severe hemophilia sufferers will have excessive bleeding after injuries, surgery and can also have spontaneous bleeding episodes. Moderate means 1%-5% factor level: about 10% of hemophilia sufferers are considered moderate. Moderate sufferers may have spontaneous bleeding episodes and will probably have prolonged bleeding after injuries. Mild means 5%-50% factor level: where about 10% of hemophilia sufferers are considered mild. These people have prolonged bleeding after a serious injury, trauma or surgery. In many cases, mild hemophilia is not discovered until there is excessive bleeding after a surgery or injury. In fact, it may not even be discovered until #########.

Though there is no cure for haemophilia, it can be controlled with regular infusions of the deficient clotting factor, i.e. factor VIII in haemophilia A or factor IX in haemophilia B. Factor replacement can be either isolated from human blood serum, recombinant, or a combination of the two. The worldwide incidence of hemophilia is estimated at more than 400,000 people. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.

Growing prevalence of the disease and the increasing use of recombinant products and prophylactic regimens are expected to drive the growth of market. However, high costs associated with the hemophilia treatment limits the adoption by end-user and inhibits the growth of this market. Several advanced and effective treatments are available in the U.S., but they may require lifelong infusion of expensive drugs that are manufactured from human plasma or through recombinant biotechnology. Biogen’s Eloctate and Alprolix are competitively priced, limiting the scope of premium pricing for pipeline long-acting products. Prophylactic treatment, however, resulted in average costs of $300,000 per year.

The hemophilia management market has been segmented by drug type, by replacement therapy and by geography. The products include Eloctate which is a recombinant DNA derived, antihemophilic factor indicated in ###### and children with Hemophilia A, Alprolix which is a recombinant DNA derived, coagulation factor IX concentrate indicated in ###### and children with Hemophilia B. Eloctate is expected to grab more market share as the incidences of hemophilia A are more than hemophilia B. Treatment with replacement therapy involves concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly dripped or injected into a vein. These infusions help replace the clotting factor that's missing or low. Similarly replacement therapy for hemophilia A with clotting factor VIII would grow faster than the therapy for hemophilia B.

Obtain the Brochure of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13634

Geographically, the two major regional markets for hemophilia treatment are Europe and North America, as the prophylaxis use of this treatment is more in Europe and it is followed by North America. According to recent data by Hemophilia Federation of America, a nearly 40% of times. Western Europe uses prophylaxis nearly 50% of the time, while the U.S. provides it 33% of the time. According to CDC statistics in 2016, one in every 5,000 newborn children is affected by hemophilia A, while one in every 30,000 is suffering from hemophilia B in the U.S. At present, Asia Pacific is a lucrative market for investment, however, high cost of treatment acts as a major restraint for the market growth. Prophylaxis treatment has been the preferred treatment option for severe hemophilia across developed countries. The rest of the world witnesses sluggish growth due to lack of awareness and high treatments costs.

The major players operating in this market include Biogen, Pfizer Inc., Baxter International Inc., Bayer Pharma AG, Novo Nordisk A/S, and Grifols International SA. and CSL Behring, Octapharma are among other significant players worldwide.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
Website: https://www.transparencymarketresearch.com/

# # #


Submitted by hawer on Wednesday, 16 January 2019 at 12:22 AM
Category: Health Care & Medical
 
Related News

Dental implants dentist Irvine, CA | best cosmetic dentist in Orange County, CA
Friday, 19 Apr 2019

Global Healthcare Supply Chain Market: Analysis and Opportunity Assessment 2019-2024
Friday, 19 Apr 2019

Global Nutraceutical Supplements Market | Growth, Trends and Forecast 2019-2024
Friday, 19 Apr 2019

Global Solder Preform Market: Analysis & Forecast 2019-2024
Friday, 19 Apr 2019

Hemp, Inc. Reports Oklahoma Next to Allow Commercial Production of Industrial Hemp
Friday, 19 Apr 2019

Related Events

The 2nd Middle East Laboratory and Diagnostics Congress
Thursday, 18 Apr 2019

The 6th SG-ANZICS Asia Pacific Intensive Care Forum (SG-ANZICS 2019)
Thursday, 18 Apr 2019

Atlanta Trauma Symposium
Thursday, 18 Apr 2019

The RAK International Psychiatry Congress
Friday, 19 Apr 2019

3rd Annual NASH Summit | April 22-25, 2019 | Boston, MA
Monday, 22 Apr 2019

Latest News

Business Printer Market Size, Share, Growth and Forecasts 2019 To 2025
Friday, 19 Apr 2019

Dental implants dentist Irvine, CA | best cosmetic dentist in Orange County, CA
Friday, 19 Apr 2019

Fruit-derived Sweeteners Market: Demand for Low-Calorie Natural Ingredients to Fuel Growth
Friday, 19 Apr 2019

Automotive Films and Sheets Market Size, Share, Growth, Trends and Forecasts 2019 To 2025
Friday, 19 Apr 2019

Automotive Films and Sheets Market Size, Share, Growth, Trends and Forecasts 2019 To 2025
Friday, 19 Apr 2019

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2019
Today is Friday, 19 April 2019

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • The 2nd Middle East Laboratory and Diagnostics Congress
  • Palo Alto Networks: Ultimate Test Drive - Migration Process (MP)
  • The 6th SG-ANZICS Asia Pacific Intensive Care Forum (SG-ANZICS 2019)
  • portable crusher plant with convenient operation
  • Atlanta Trauma Symposium

  • Latest Jobs
    Sorry, there are currently no entries posted here.